GO:0005178 integrin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005178 integrin binding is a molecular function defined as binding to an integrin, with the synonym integrin ligand [QuickGO].
• Integrin binding is central to cell adhesion, extracellular matrix (ECM) recognition, and bidirectional signaling across the plasma membrane [1,2,4].
• Key integrin-binding proteins include fibronectin, vitronectin, talin, and galectin-3, which engage distinct integrin heterodimers [2,3,5,8].
• Integrin binding can activate latent TGF-beta1 via alphaVbeta6, linking ECM binding to fibrosis and inflammation.
• Therapeutic antibodies such as vedolizumab target integrin binding specificity to treat inflammatory bowel diseases.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect integrin-binding mechanisms and validate drug targets [1,4,8].
Description
Integrin binding (GO:0005178) is a molecular function that describes the physical interaction between a protein or ligand and an integrin receptor. Integrins are heterodimeric cell-surface receptors that mediate cell-ECM and cell-cell adhesion, and their binding partners dictate downstream signaling, cytoskeletal remodeling, and gene expression [1,2,4]. This GO term is critical for researchers studying adhesion, migration, immune surveillance, and tissue homeostasis because it defines the molecular recognition events that initiate these processes [2,5,8]. The specificity of integrin binding is exemplified by vedolizumab, a therapeutic antibody that selectively binds alpha4beta7 integrin and blocks its interaction with mucosal addressin cell adhesion molecule-1 (MAdCAM-1), thereby reducing inflammatory bowel disease pathology. Similarly, fibronectin-binding bacteria exploit integrin-mediated uptake to invade host cells, highlighting the pathophysiological relevance of this function. Understanding integrin binding at the molecular level enables the design of inhibitors, biologics, and CRISPR-based disease models [1,4,8].
integrin binding At A Glance
| GO ID | GO:0005178 |
|---|---|
| GO term | integrin binding |
| Ontology | molecular_function |
| Synonym | integrin ligand |
| Definition | Binding to an integrin. |
| Major function | Mediates physical interaction with integrin heterodimers, initiating adhesion and signaling. |
| Example ligands | Fibronectin, vitronectin, talin, galectin-3, tropoelastin [2,3,5,6,8] |
| Related disease | Inflammatory bowel diseases, fibrosis, cancer [1,4] |
| Research methods | CRISPR KO, knock-in, surface plasmon resonance, mechanointeractome analysis [1,4,8] |
What Is GO:0005178?
According to QuickGO, GO:0005178 integrin binding is the molecular function of binding to an integrin. The term carries the synonym integrin ligand. In practice, this means a protein, peptide, or small molecule physically associates with an integrin heterodimer, often through specific recognition motifs such as the RGD sequence in fibronectin or vitronectin [2,5]. This binding event can be direct or facilitated by cofactors like calcium and integrin-binding proteins.
Why Is integrin binding Important in Cell Biology?
Integrin binding is a fundamental molecular function that governs how cells sense and respond to their extracellular environment. It is essential for embryonic development, immune cell trafficking, wound healing, and tissue repair [1,2,4]. Dysregulated integrin binding contributes to chronic inflammation, fibrosis, and cancer progression, making it a high-value target for therapeutic intervention [1,4]. Moreover, integrin binding is mechanosensitive, with proteins like talin transmitting force across the membrane to regulate cytoskeletal dynamics. Understanding this function at the atomic and cellular level is therefore critical for both basic biology and translational medicine.
• Integrin binding mediates cell adhesion to the ECM, a prerequisite for tissue architecture and integrity [2,5].
• It activates latent TGF-beta1, a key driver of pulmonary inflammation and fibrosis.
• Selective integrin binding by vedolizumab is clinically validated for inflammatory bowel diseases.
• Fibronectin-binding bacteria exploit integrin binding for host cell uptake and infection.
• Galectin-3 binding to alpha5beta1 integrin modulates cell signaling and cancer progression.
• Talin-integrin binding transmits mechanical force and regulates focal adhesion dynamics.
• Calcium and integrin-binding protein 1-like facilitates cellular immunity in insects, showing evolutionary conservation.
• Tropoelastin-integrin alphaVbeta3 binding follows a fuzzy model, relevant to elastic fiber assembly.
• Integrin binding is a target for anti-inflammatory and anti-fibrotic drug discovery [1,4].
• CRISPR screens can identify novel integrin-binding regulators and modifiers [1,4,8].
Molecular Mechanism of integrin binding
Ligand recognition and binding specificity
In simple terms: Integrins recognize specific sequences or shapes on their binding partners.
Integrin binding is highly specific and depends on the integrin heterodimer composition. For example, vedolizumab selectively binds alpha4beta7 integrin and blocks its interaction with MAdCAM-1, a mechanism used to treat inflammatory bowel diseases. Fibronectin-binding bacteria engage integrins through fibronectin bridges, leading to bacterial uptake. Vitronectin contains an RGD motif that binds alphaV integrins, and this interaction is critical for cell adhesion and migration. Galectin-3 binds alpha5beta1 integrin in pore-suspended biomembranes, demonstrating carbohydrate-dependent recognition.
Conformational activation and signaling
In simple terms: Binding causes the integrin to change shape and send signals into the cell.
Upon ligand binding, integrins undergo conformational changes that propagate from the extracellular domain to the cytoplasmic tail, activating intracellular signaling pathways [4,8]. The integrin alphaVbeta6 binds and activates latent TGF-beta1, a process that requires mechanical force and leads to TGF-beta1 release, thereby regulating pulmonary inflammation and fibrosis. Talin binding to the integrin beta-cytoplasmic domain is a key step in integrin activation and force transmission, as revealed by force-directed mechanointeractome studies.
Cofactors and regulatory proteins
In simple terms: Other proteins and ions help or hinder integrin binding.
Calcium and integrin-binding protein 1-like interacts with an integrin alpha-cytoplasmic domain to facilitate cellular immunity in Helicoverpa armigera, indicating that calcium-binding proteins modulate integrin function. Tropoelastin binding to integrin alphaVbeta3 follows a fuzzy binding model, where multiple weak interactions cooperate to achieve specificity and affinity. These examples illustrate that integrin binding is not a simple lock-and-key event but is regulated by cofactors and the local membrane environment [3,6,7].
Mechanical force and mechanotransduction
In simple terms: Physical pulling forces can strengthen or weaken integrin binding.
Integrin binding is mechanosensitive. Force-directed mechanointeractome analysis of talin-integrin interactions shows that mechanical force stabilizes the talin-integrin bond and recruits additional proteins to focal adhesions. This mechanotransduction is essential for cell migration, ECM remodeling, and tissue homeostasis. The alphaVbeta6 integrin-mediated activation of latent TGF-beta1 also requires force, linking mechanical cues to cytokine signaling.
Key Genes Involved in GO:0005178 integrin binding
The following genes and proteins are central to integrin binding (GO:0005178) and are frequently studied in adhesion, signaling, and disease research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGA4 | Integrin alpha4 subunit; forms alpha4beta7 with ITGB7 | Target of vedolizumab in IBD |
| ITGB7 | Integrin beta7 subunit; pairs with alpha4 | Mediates lymphocyte homing to gut |
| ITGAV | Integrin alphaV subunit; binds vitronectin, fibronectin | Fibrosis, cancer, TGF-beta activation [4,5] |
| ITGB6 | Integrin beta6 subunit; pairs with alphaV | Activates latent TGF-beta1 in pulmonary fibrosis |
| ITGB1 | Integrin beta1 subunit; binds fibronectin, galectin-3 | Cell adhesion, cancer progression [2,3] |
| ITGA5 | Integrin alpha5 subunit; pairs with beta1 | Galectin-3 binding, fibronectin uptake |
| FN1 | Fibronectin; ECM ligand for multiple integrins | Bacterial uptake, cell migration |
| VTN | Vitronectin; RGD-containing ligand | Cell adhesion, wound healing |
| TLN1 | Talin-1; links integrin to actin cytoskeleton | Mechanotransduction, focal adhesion |
| LGALS3 | Galectin-3; binds alpha5beta1 integrin | Cancer, fibrosis, immune regulation |
| CIB1 | Calcium and integrin-binding protein 1 | Integrin activation, cell survival |
| CIB1L | CIB1-like; interacts with integrin alpha domain | Cellular immunity in insects |
| ELN | Elastin; tropoelastin binds alphaVbeta3 | Elastic fiber assembly |
| MADCAM1 | Mucosal addressin cell adhesion molecule-1 | Ligand for alpha4beta7 in gut |
| TGFB1 | Latent TGF-beta1; activated by alphaVbeta6 | Fibrosis, inflammation |
| ITGB3 | Integrin beta3 subunit; pairs with alphaV | Tropoelastin binding, platelet function |
| ITGAL | Integrin alphaL subunit; forms LFA-1 | Immune cell adhesion |
| ITGB2 | Integrin beta2 subunit; pairs with alphaL | Leukocyte adhesion deficiency |
How Is integrin binding Regulated?
Integrin binding is regulated at multiple levels, including conformational activation by talin and kindlins, post-translational modifications, and the lipid composition of the membrane. Calcium and integrin-binding proteins can modulate the affinity of integrins for their ligands. Mechanical force acts as a regulatory cue, strengthening talin-integrin bonds and promoting focal adhesion assembly. Additionally, the binding of galectin-3 to alpha5beta1 integrin is influenced by membrane curvature and pore suspension, indicating that the local membrane environment regulates integrin binding. Therapeutic antibodies like vedolizumab can selectively antagonize specific integrin-ligand interactions, providing a means to regulate integrin binding in disease.
integrin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITGA4/ITGB7 | Inflammatory bowel diseases | Knockout mice or human T-cell lines with ITGA4 KO |
| ITGAV/ITGB6 | Pulmonary fibrosis | Lung epithelial cell lines with ITGB6 KO or point mutations |
| LGALS3/ITGA5/ITGB1 | Cancer progression | Cancer cell lines with LGALS3 overexpression or ITGA5 KO |
| FN1/ITGB1 | Bacterial uptake and infection | Fibronectin-binding bacterial infection models in ITGB1 KO cells |
| TLN1/ITGB1 | Mechanotransduction disorders | Talin-1 knock-in mutations to disrupt integrin binding |
Inflammatory bowel diseases (IBD)
Integrin binding plays a central role in lymphocyte trafficking to the gut. The alpha4beta7 integrin binds MAdCAM-1 on endothelial cells, mediating lymphocyte homing to intestinal mucosa. Vedolizumab, a humanized antibody that selectively binds alpha4beta7, blocks this interaction and is approved for ulcerative colitis and Crohn's disease. This exemplifies how targeting integrin binding can yield effective anti-inflammatory therapies.
Pulmonary fibrosis and inflammation
The integrin alphaVbeta6 binds and activates latent TGF-beta1, a key driver of pulmonary fibrosis. This binding event requires mechanical force and leads to TGF-beta1 release, promoting fibroblast activation and collagen deposition. Inhibiting alphaVbeta6 integrin binding is a therapeutic strategy for fibrotic lung diseases.
Cancer progression and metastasis
Integrin binding to ECM components such as fibronectin and vitronectin supports tumor cell adhesion, migration, and survival. Galectin-3 binding to alpha5beta1 integrin modulates signaling pathways that promote cancer progression. Fibronectin-binding bacteria can exploit integrin-mediated uptake, which may contribute to infection-associated cancers. Targeting integrin binding is an active area in oncology drug development.
From integrin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ITGA4 abolish alpha4beta7 integrin binding? | ITGA4 knockout cell line (e.g., Jurkat) |
| Can point mutations in ITGB6 prevent latent TGF-beta1 activation? | ITGB6 point-mutant knock-in lung epithelial cells |
| Does galectin-3 binding to alpha5beta1 require specific glycans? | LGALS3 knock-in with tagged galectin-3 and ITGA5 KO |
| How does talin-integrin binding respond to force? | Talin-1 tagged knock-in for mechanointeractome analysis |
| Can overexpression of vitronectin enhance cell adhesion? | VTN overexpression in fibroblast cell lines |
| Does CIB1L modulate integrin binding in immunity? | CIB1L knockout or overexpression in insect cells |
How to Study the integrin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing integrin-antibody interactions |
| Mechanointeractome analysis | Force-dependent binding stability | Talin-integrin mechanotransduction |
| CRISPR knockout screens | Gene essentiality for integrin binding | Identifying novel regulators of adhesion |
| Pore-suspended biomembranes | Ligand binding in lipid bilayers | Galectin-3-integrin interaction |
| Flow cytometry | Cell surface integrin expression and ligand binding | Vedolizumab binding to alpha4beta7 |
| Immunoprecipitation | Protein-protein interactions | CIB1L-integrin alpha domain binding |
| Atomic force microscopy | Unbinding forces and mechanical properties | Tropoelastin-integrin binding |
| ELISA | Quantitative ligand binding | Vitronectin-integrin binding |
Surface plasmon resonance (SPR) and biophysical assays
SPR measures real-time binding kinetics between integrins and their ligands, providing affinity constants and kinetic rates. This method has been used to characterize vedolizumab binding to alpha4beta7 integrin and galectin-3 binding to alpha5beta1. It is essential for validating direct integrin-ligand interactions.
Mechanointeractome analysis
Force-directed mechanointeractome studies use magnetic tweezers or atomic force microscopy to probe how mechanical force affects talin-integrin binding. This approach revealed force-dependent stabilization of the talin-integrin bond and identified new mechanosensitive interactions.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate integrin binding. For example, knocking out ITGA4 or ITGB7 abolishes alpha4beta7 expression and binding to MAdCAM-1, validating the specificity of vedolizumab. Similar screens can uncover novel regulators of integrin function.
Advanced imaging and membrane models
Pore-suspended biomembranes and single-molecule imaging allow visualization of integrin binding in a near-native lipid environment. Galectin-3 binding to alpha5beta1 integrin was studied using such biomembranes, revealing the importance of membrane curvature and lipid composition. These methods complement cellular assays.
How CRISPR Can Be Used to Study GO:0005178 integrin binding
Knockout
CRISPR knockout of integrin subunit genes (e.g., ITGA4, ITGB7, ITGB6) completely abolishes specific integrin heterodimers, providing a clean background to study binding specificity. For example, ITGA4 knockout cells cannot bind MAdCAM-1, confirming the role of alpha4beta7 in lymphocyte homing. Knockout of ITGB6 prevents alphaVbeta6-mediated TGF-beta1 activation, linking integrin binding to fibrosis.
Point Mutation
Point mutations can disrupt specific binding interfaces without affecting overall integrin structure. For instance, mutating the RGD-binding site in integrin beta subunits can selectively impair ligand binding while preserving heterodimer formation. Such models are valuable for dissecting the contribution of individual residues to integrin binding affinity and signaling [4,8].
Knock-in
Knock-in of tagged integrins (e.g., GFP or HA tags) allows real-time tracking of integrin binding and trafficking in live cells. Tagged talin-1 knock-in models have been used for mechanointeractome studies to measure force-dependent binding. Knock-in of disease-associated mutations in ITGB6 can model impaired TGF-beta1 activation in fibrosis.
Overexpression
Overexpression of integrin ligands such as fibronectin or vitronectin can enhance integrin binding and downstream signaling. Overexpressing galectin-3 in cancer cells increases alpha5beta1 integrin binding and promotes migration. Overexpression models are useful for gain-of-function studies and for testing inhibitors of integrin binding.
How EDITGENE Supports integrin binding Research
Researchers studying integrin binding-related genes often need to determine whether a candidate gene is causally involved in adhesion, signaling, or disease. CRISPR-based models provide the precision required to dissect these mechanisms, from complete knockout to subtle point mutations and tagged knock-ins. EDITGENE offers a comprehensive suite of services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for integrin binding research.
Frequently Asked Questions About integrin binding
What is GO:0005178 integrin binding?
GO:0005178 is a Gene Ontology molecular function term defined as binding to an integrin. It describes the physical interaction between a ligand and an integrin heterodimer, which is central to cell adhesion and signaling [QuickGO].
What genes are involved in integrin binding?
Key genes include ITGA4, ITGB7, ITGAV, ITGB6, ITGB1, ITGA5, FN1, VTN, TLN1, LGALS3, and CIB1, among others [1,2,3,4,5,7,8].
How does integrin binding activate TGF-beta1?
The integrin alphaVbeta6 binds latent TGF-beta1 and, upon mechanical force, releases active TGF-beta1, a mechanism that regulates pulmonary inflammation and fibrosis.
What diseases are associated with abnormal integrin binding?
Inflammatory bowel diseases, pulmonary fibrosis, and cancer progression are linked to dysregulated integrin binding [1,3,4].
What is the role of talin in integrin binding?
Talin binds the integrin beta-cytoplasmic domain, linking integrins to the actin cytoskeleton and transmitting mechanical force, as shown by mechanointeractome studies.
How can CRISPR be used to study integrin binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of integrin genes and their ligands to dissect binding mechanisms and disease relevance [1,4,8].
What is vedolizumab and how does it relate to integrin binding?
Vedolizumab is a therapeutic antibody that selectively binds alpha4beta7 integrin and blocks its interaction with MAdCAM-1, used to treat inflammatory bowel diseases.
Which methods measure integrin binding affinity?
Surface plasmon resonance, ELISA, flow cytometry, and atomic force microscopy are commonly used to measure integrin binding affinity and kinetics [1,3,5,6].
What is the fuzzy binding model of tropoelastin-integrin interaction?
It describes how tropoelastin binds integrin alphaVbeta3 through multiple weak interactions that collectively achieve specificity and affinity.
Can integrin binding be targeted for cancer therapy?
Yes, blocking integrin binding to ECM components such as fibronectin and vitronectin is an active strategy in cancer drug development [3,5].
Conclusion
Integrin binding (GO:0005178) is a fundamental molecular function that underlies cell adhesion, signaling, and mechanotransduction. Its dysregulation contributes to inflammatory diseases, fibrosis, and cancer, making it a prime therapeutic target. The specificity of integrin-ligand interactions, exemplified by vedolizumab and alphaVbeta6-mediated TGF-beta1 activation, highlights the importance of precise molecular understanding. CRISPR-based models, combined with biophysical and imaging methods, are indispensable for dissecting integrin binding mechanisms and validating drug targets. EDITGENE provides end-to-end solutions to accelerate this research.
References
- 1. Soler D et al.. 2009. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.. J Pharmacol Exp Ther 330(3):864-75 PMID: 19509315
- 2. Hoffmann C et al.. 2011. Integrin-mediated uptake of fibronectin-binding bacteria.. Eur J Cell Biol 90(11):891-6 PMID: 21561684
- 3. Sarangi NK et al.. 2022. Galectin-3 Binding to α(5)β(1) Integrin in Pore Suspended Biomembranes.. J Phys Chem B 126(48):10000-10017 PMID: 36413808
- 4. Munger JS et al.. 1999. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.. Cell 96(3):319-28 PMID: 10025398
- 5. Schvartz I et al.. 1999. Vitronectin.. Int J Biochem Cell Biol 31(5):539-44 PMID: 10399314
- 6. Ozsvar J et al.. 2021. Fuzzy binding model of molecular interactions between tropoelastin and integrin alphaVbeta3.. Biophys J 120(15):3138-3151 PMID: 34197806
- 7. Zhang MM et al.. 2022. Calcium and integrin-binding protein 1-like interacting with an integrin α-cytoplasmic domain facilitates cellular immunity in Helicoverpa armigera.. Dev Comp Immunol 131:104379 PMID: 35231466
- 8. Chakraborty S et al.. 2019. Force-Directed "Mechanointeractome" of Talin-Integrin.. Biochemistry 58(47):4677-4695 PMID: 31393109
